Andere Sprachen TriSalus Life Sciences, Inc.

Aktien

TLSI

US89680M1018

TLSI

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 12.06.2024			% 5 Tage	% 1. Jan.
6.03 ^USD	+1.17%		-15.78%	-28.64%

03.06.	TriSalus Life Sciences, Inc. hebt klinische Daten der Phase 1b Perio-02-Studie hervor	CI
30.05.	TRISALUS LIFE SCIENCES, INC. : Canaccord Genuity behält seine Kaufempfehlung bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting	03.06.
TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial	03.06.
TriSalus Life Sciences Launches Warrant Exchange Offer	24.05.
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants	24.05.
TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	15.05.
TriSalus Reports Q1 2024 Financial Results and Business Update	15.05.
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024	15.05.
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	07.05.
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors	07.05.
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	06.05.
TriSalus Life Sciences Obtains $50 Million Debt Facility	01.05.
Trisalus Life Sciences, Inc. and Trisalus Operating Life Sciences, Inc. Enters into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP	30.04.
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	30.04.
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC	30.04.
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	01.04.
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01.04.
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Reports Q4 Revenue $5.7M	01.04.
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting	26.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen TriSalus Life Sciences, Inc.

Aktien

TLSI

US89680M1018

TLSI

Andere Sprachen

Filter